Equities

Fuso Pharmaceutical Industries Ltd

4538:TYO

Fuso Pharmaceutical Industries Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,250.00
  • Today's Change0.00 / 0.00%
  • Shares traded8.50k
  • 1 Year change+7.97%
  • Beta0.8581
Data delayed at least 20 minutes, as of Aug 30 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fuso Pharmaceutical Industries, Ltd. is a Japan-based company principally involved in the manufacture and sale of pharmaceuticals and medical equipment for medical purposes. The Company operates in two business segments. The Pharmaceuticals segment is involved in manufacture and sale of pharmaceutical products, including injectable drugs, which mainly focus on infusion solution, dialysis fluid for artificial kidney, as well as the manufacture and sale of medical equipment and instruments. The Real Estate segment is engaged in the leasing of real estate properties.

  • Revenue in JPY (TTM)56.52bn
  • Net income in JPY1.53bn
  • Incorporated1937
  • Employees1.31k
  • Location
    Fuso Pharmaceutical Industries Ltd1-7-10, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
  • Phone+81 662316887
  • Fax+81 669692341
  • Websitehttps://www.fuso-pharm.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Solasia Pharma KK159.00m-1.29bn10.90bn24.00--5.08--68.57-7.36-7.360.90659.850.06390.85490.52566,625,000.00-51.68-48.57-59.50-58.8331.4571.01-808.81-300.893.42-61.240.0219---43.5014.1856.36------
Perseus Proteomics Inc96.49m-901.50m11.45bn25.00--5.80--118.62-73.63-73.637.83134.050.04433.2111.843,859,520.00-41.36-41.34-43.27-43.4387.7391.72-934.32-891.2619.91--0.00--6.58-18.31-40.34--60.30--
Symbio Pharmaceuticals Ltd3.70bn-3.42bn12.26bn109.00--1.90--3.32-81.51-81.5187.41140.730.44942.894.7433,903,380.00-41.64-19.18-46.17-23.6279.4065.84-92.66-24.329.01--0.00---44.157.82-266.45--42.39--
Ohki Healthcare Holdings Co Ltd340.31bn2.08bn12.72bn632.005.960.43525.360.0374151.56151.5624,771.522,077.282.5413.314.54538,470,000.001.491.856.448.425.116.160.58590.71780.8853--0.169813.929.925.301.281.51-5.345.92
ReproCell Inc2.49bn-178.74m13.26bn96.00--1.52--5.33-2.03-2.0328.7293.570.28264.766.6325,940,160.00-2.03-7.35-2.20-8.0048.9939.83-7.18-27.169.99--0.00---17.8317.3989.71--13.27--
RaQualia Pharma Inc2.30bn-673.00m13.81bn67.00--2.44--6.01-31.12-31.12106.28261.020.26523.822.8934,300,980.00-7.772.13-8.562.2684.7888.49-29.285.323.55--0.39720.00-34.8520.62-144.74--0.0967--
Oncolys Biopharma Inc31.38m-1.82bn14.19bn34.00--9.40--452.13-95.02-95.021.6267.900.01670.000.2245923,058.80-97.25-45.75-116.54-51.860.0060.46-5,813.82-233.667.01--0.2052---93.54-17.86-68.72--28.18--
CanBas Co Ltd (Parent)0.00-1.21bn15.27bn12.00--6.52-----67.63-67.630.00129.880.00-------53.54-62.25-56.62-70.91--------25.09----------2.77------
Stella Pharma Corp269.49m-759.81m17.83bn44.00--6.34--66.18-24.30-24.308.6282.710.05940.05173.986,124,796.00-16.73-22.50-17.64-24.8380.37---281.94-488.6515.60-943.380.2481--17.65--1.94---5.87--
Fuso Pharmaceutical Industries Ltd56.52bn1.53bn21.27bn1.31k12.560.51595.640.3762179.11179.116,607.604,361.000.74543.082.3543,245,600.002.021.913.503.0925.6726.922.712.690.939336.590.276741.108.613.76-14.219.029.13-2.64
TAIKO PHARMACEUTICAL CO LTD6.49bn-2.33bn21.27bn208.00--2.61--3.28-46.91-46.91130.40160.860.44741.913.7131,211,540.00-16.07---19.68--49.37---35.92--2.95--0.2437--21.43--26.23------
Astena Holdings Co Ltd53.22bn2.10bn21.35bn1.40k9.840.72584.910.401252.9252.921,343.58717.870.81053.422.7337,904,980.003.182.495.774.4433.1825.333.932.320.889--0.343944.924.73-2.85100.61-3.8538.5411.38
StemRIM Inc0.00-2.13bn27.50bn44.00--2.93-----34.87-34.870.00152.360.00----0.00-20.52-6.71-20.87-6.83-------45.8099.90-8,295.360.00--10,128.0663.68108.64------
CellSeed Inc199.47m-957.04m30.45bn35.00--13.89--152.64-30.72-30.726.4063.290.08921.657.915,699,172.00-42.79-49.69-46.02-54.5555.3863.66-479.79-428.6216.42-5,460.760.0651--50.39-28.62-11.43--80.73--
Data as of Aug 30 2024. Currency figures normalised to Fuso Pharmaceutical Industries Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

10.75%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 31 Jul 2024216.50k2.29%
The Vanguard Group, Inc.as of 08 Aug 2024181.91k1.93%
Dimensional Fund Advisors LPas of 08 Aug 2024176.70k1.87%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Sep 2023157.20k1.66%
Daiwa Asset Management Co. Ltd.as of 31 Jul 202497.90k1.04%
Nikko Asset Management Co., Ltd.as of 15 Sep 202389.80k0.95%
Mitsubishi UFJ Asset Management Co., Ltd.as of 25 Sep 202338.60k0.41%
Norges Bank Investment Managementas of 31 Dec 202326.80k0.28%
Dimensional Fund Advisors Ltd.as of 08 Aug 202419.80k0.21%
Asset Management One Co., Ltd.as of 08 Aug 202410.40k0.11%
More ▼
Data from 30 Jun 2024 - 22 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.